Therapeutic advantages of an inotropic vasodilator in endotoxin shock.
D000804:Angiotensin II / Q000627:therapeutic use*; D000818:Animals; D004285:Dogs; D004926:Escherichia coli; D006321:Heart / Q000187:drug effects*; D007545:Isoproterenol / Q000627:therapeutic use*; D008729:Methoxamine / Q000494:pharmacology*; D009638:Norepinephrine / Q000627:therapeutic use*; D011311:Pressoreceptors / Q000187:drug effects; D012077:Renal Artery; D012772:Shock, Septic / Q000628:therapy*; D013328:Strophanthins / Q000627:therapeutic use*; D014655:Vascular Resistance
D013328:Strophanthins; D000804:Angiotensin II; D008729:Methoxamine; D007545:Isoproterenol; D009638:Norepinephrine